Nutritional and Metabolic Diseases

Symptoms and General Pathology

All Conditions

Digestive System Diseases

Neoplasms

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Gland and Hormone Related Diseases

Rare Diseases

Overweight

Syndrome

Obesity

Fatty Liver

Polycystic Ovary Syndrome

Overnutrition

Nutrition Disorders

Body Weight

Liver Diseases

Gastrointestinal Diseases

Cysts

Ovarian Cysts

Ovarian Diseases

Adnexal Diseases

Genital Diseases, Female

Genital Diseases

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Gonadal Disorders

Endocrine System Diseases

Visceral Steatosis

All Drugs and Chemicals

Hypoglycemic Agents

Hematinics

Reproductive Control Agents

Anti-Obesity Agents

Gastrointestinal Agents

Hormones

Metformin

Liver Extracts

Contraceptive Agents

Exenatide

Contraceptives, Oral

Contraceptives, Oral, Combined

Glucagon

Glucagon-Like Peptide-1 Receptor Agonists

Glucagon-Like Peptide 1

Incretins

Hormone Antagonists

PCOS, medication naive; 10 girls with PCOS will receive 2 doses of Byetta.

Up to 45 girls with PCOS with no exposure to hormone therapy or metformin in the preceding 6 months.

Up to 10 girls with PCOS and 6 months of therapy with combined oral contraceptives (COCPs) prior to study procedures.

Up to 10 girls with PCOS and 6 months of therapy with metformin prior to study procedures

10 participants will receive 2 doses of Byetta, one at 7 PM the night prior to metabolic study and the second 30 min before ingestion of glucola

Byetta 5Mcg Pen Injection

Melanie Cree Green, MD, PhD

Women with polycystic ovarian syndrome (PCOS) have increased rates of hepatic steatosis compared to weight similar women with regular menses. It is unclear if this is related to high testosterone or insulin resistance. The investigators will assess hepatic glucose release, rates of lipolysis and hepatic de novo lipogenesis in the fasted and postprandial state to determine if alterations in the processes contribute to hepatic steatosis. Participants will be overweight, sedentary girls with or without PCOS. Those with PCOS will either be medication naive, or must be taking metformin or combined oral contraceptives (COCPs) for a period of at least 6 months prior to study procedures.

Hepatic glucose release will be assessed with a stable isotope glycerol tracer, lipolysis with a glycerol tracer, and hepatic de novo lipogenesis with an acetate tracer. Data will be collected fasting and after a glucose challenge. The degree of hepatic steatosis and abdominal fat partitioning will be assessed with Magnetic Resonance Imaging (MRI), and total body composition with Dual-energy X-ray absorptiometry (DEXA).

Liver and Fat Regulation in Overweight Adolescent Girls

Assessment of Hepatic Glucose and Fat Regulation in Overweight Adolescent Girls

Data will only be shared with IRB approved personnel.

Participants will undergo a 75 gram oral glucose tolerance test, and whole body insulin sensitivity will be expressed as Si, calculated via the oral minimal model.

Apnea Hypopnea Index (AHI) will be measured using WatchPAT. In children and adolescents the scale that will be used is AHI\>5 is considered mild sleep apnea. The higher the AHI, indicates more severe sleep apnea.

The AHI is the number of times you have apnea or hypopnea during one night, divided by the hours of sleep.

Normal sleep: An AHI of fewer than five events, on average, per hour Mild sleep apnea: An AHI of five to 14 events per hour Moderate sleep apnea: An AHI of 15 to 29 events per hour Severe sleep apnea: An AHI of 30 or more events per hour

Sleep duration will be assessed using home actigraphy using the Philips Actigraph wrist-worn watch, and collects 7 days of data.

Change in expression of stool microbiome species by comparing the PCOS group to samples collected from a control group without PCOS. The 5 species with the most significant will be identified and reported from a Manhattan Plot (% rate of appearance): the values above 0 represent species that are greater in the control group than in PCOS and values below 0 represent species that are greater in PCOS than in the control group.

Targeted amino acid metabolomics will be performed to measure glutamate

Targeted lipid metabolomics will be performed to measure 16n1

Targeted bile acid metabolomics will be performed to measure sphingosine-1-phospate

Hepatic glucose release will be measured by the rate of appearance of a glucose tracer.

Hepatic phosphate relative concentrations will be measured with 31 phosphorus magnetic resonance spectroscopy

Rate of lipolysis will be measured by the rate of appearance of a glycerol tracer.

Amount of fat in the liver measured by MRI and calculated via the Dixon method as the proton density hepatic fat fraction, which ranges from 0-75%. Greater than 5% is considered extra fat in the liver.

Hepatic de novo lipogenesis will be measured by with an acetate tracer.

Spots Global Cancer Trial Database for byetta 5mcg pen injection